Completed PHASE3 INTERVENTIONAL 3-arm NCT02282761

A Trial to Assess the Antipsychotic Efficacy of ITI-007

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Sponsor: Intra-Cellular Therapies, Inc.

Conditions Schizophrenia

Interventions ITI-007 Placebo

Updated 8 times since 2017 Last updated: Sep 16, 2025 Started: Nov 30, 2014 Primary completion: Jul 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Intra-Cellular Therapies, Inc. and has accumulated 8 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

8 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Nov 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intra-Cellular Therapies, Inc.

Data source: Intra-Cellular Therapies, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Escondido, United States , Fort Lauderdale, United States , Garden Grove, United States , Little Rock, United States , Long Beach, United States , Marlton, United States , Rockville, United States , San Diego, United States , Springdale, United States and 1 more location